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Abstract: Vitamin D, besides its classical role in bone metabolism, plays a distinct role in multiple
pathways of the feto-maternal unit. Calcitriol is the major active ligand of the nuclear vitamin D
receptor (VDR). The vitamin D receptor (VDR) is expressed in different uteroplacental parts and
exerts a variety of functions in physiologic pregnancy. It regulates decidualisation and implantation,
influences hormone secretion and placental immune modulations. This review highlights the role
of the vitamin D receptor in physiologic and disturbed pregnancy, as preeclampsia, fetal growth
restriction, gestational diabetes and preterm birth. We discuss the existing literature regarding
common VDR polymorphisms in these pregnancy disorders.
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1. Introduction
The vitamin D endocrine system was formerly known as a key player in calcium and phosphate
homoeostasis and in regulation of bone remodelling [1]. Hence, nowadays it is common knowledge,
that the vitamin D endocrine system takes part in many non-classical pathways. Vitamin D influences
maternal and fetal cell differentiation and cell growth, immune regulation, insulin secretion and
anti-proliferative processes [2–5]. Therefore, this ligand is of special interest as it is involved in many
diseases like autoimmune disorders, and type 2 diabetes mellitus (T2DM) [6,7].
The name vitamin is misleading, as in humans, only a small amount of vitamin D is obtained
through dietary intake, while vitamin D is largely generated in the skin with exposure via photochemical
conversion of 7-dehydrocholesterol to pre-vitamin D3, and the latter is sequentially metabolized in the
liver and kidneys [8]. Extrarenal 1,25(OH)2D3 is metabolized by the colon, pancreas, immune system,
endothelial cells and the placenta [9].
1.1. Vitamin D Receptor (VDR) Signaling
1α,25-(OH)2D (calcitriol) is the major active ligand of the Vitamin D receptor (VDR). VDR
is part of the nuclear steroid hormone receptor family; and recruits another receptor of this
group, for example, retinoid X receptor α to form a heterodimer. This complex works as a
transcriptional activator of numerous genes, via VDR response elements of the targeted genes [10].
However, vitamin D can also exert rapid non-genomic effects, probably via VDR located within the
plasma membrane [11,12].This rapid pathway works via specific enzymes as protein kinase C and
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mitogen-activated protein kinase [13]. They regulate cell proliferation and cell differentiation, invasive
processes and apoptosis.
1.2. VDR Gene and Polymorphisms
VDR is encoded by a capacious gene (>100 kb), it lies on the chromosome 12q12-14 [14]. The VDR
gene includes two promoter regions, eight coding exons (namely, 2–9), and six untranslated exons
(1A–1F). In the VDR gene, single nucleotide polymorphisms (SNPs) occur quite frequently [15].
Every genetic variant is called a polymorphism if it appears in at least 1% of the population.
Recently, multiple loci in VDR binding proteins and the modulating enzymes CYP2R1, CYP24A1,
CYP27B1, and CYP27A1 genes have been linked to vitamin D levels [16,17].
Since the discovery of the VDR gene, common SNPs have been specified in the gene [15].
VDR gene has four precise described di-allelic polymorphisms: BsmI (A > G, rs1544410) and ApaI
(A > C, rs7975232) on the last intron, and FokI (C > T, rs10735810) and TaqI (T > C, rs731236)
polymorphisms lie on the coding exons [18,19]. Several studies investigated these SNPs and associated
them with a couple of diseases [15,20,21] Therefore, VDR allelic variants and different expressions
of the receptor play a key role in a number of health concerns, as e.g., breast cancer or auto-immune
diseases [22]. Hence, the role of VDR and its allelic variants in pregnancy is not yet clarified [23].
A graphical view of VDR activation and its polymorphisms is presented in Figure 1.
The aim of this review was to summarize the existing knowledge about the role of VDR expression,
function and polymorphisms in common pregnancy disorders.
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Figure 1. Vitamin D receptor expression and polymorphism: Vitamin D receptor (VDR) is a part of 
the nuclear steroid family and is also expressed in the plasma membrane. The major active ligand of 
VDR is 1α,25-(OH)2D (calcitriol). In nucleus, VDR recruits retinoid X receptor (RXR) to form a 
heterodimer, which binds to vitamin D response element (VDRE) and modulates the transcription of 
numerous genes. VDR gene is located on the chromosome 12q12-14, which consists of eight protein 
exons (namely, 2–9) and six untranslated exons (1A–1F). VDR has four well-characterized di-allelic 
polymorphisms: BsmI and ApaI on the last intron, FokI and TaqI on the coding sequence. Among these 
polymorphisms ApaI, FokI and TaqI are linked to gestational diabetes mellitus (GDM), ApaI and FokI 
are linked to preterm birth.  
Figure 1. Vitamin D receptor expression and pol or hism: Vitamin D receptor (VDR) is a part of
the nuclear steroid family and is also expressed in the plasma membrane. The major active ligand
of VDR is 1α,25-(OH)2D (calcitriol). In nucleus, VDR recruits retinoid X receptor (RXR) to form
a heterodimer, which binds to vitamin D response element (VDRE) and modulates the transcription
of numerous genes. VDR gene is located on the chromosome 12q12-14, which consists of eight
protein exons (namely, 2–9) and six untranslated exons (1A–1F). VDR has four well-characterized
di-allelic polymorphisms: BsmI and ApaI on the last intron, FokI and TaqI on the coding sequence.
Among these polymorphisms ApaI, FokI and TaqI are linked to gestational diabetes mellitus (GDM),
ApaI and FokI are linked to preterm birth.
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2. VDR Expression in Physiologic Pregnancy
Trophoblasts are a major source of 1,25[OH]2D3 and during pregnancy it is elevated two folds [5].
It regulates decidualisation, implantation, lactogen expression. Furthermore, Vitamin D influences
human chorionic gonadotropin (HCG), progesterone and estrogen secretion, calcium uptake into the
placenta and placental immune modulations [24–27].
Placenta is also a major site for conversion of 25(OH)D3 to 1,25(OH)2D3 via CYP27B1 [28].
Placental calcitriol synthesis begins early in gestation, as placental expression of CYP27B1 mRNA is
already high in the first trimester [28]. Increased levels of Calcitriol suppresses CYP27B1 transcription
in trophoblasts [29,30], in contrary CYP24A1 expression is upregulated. This effect works via
ligand-bound VDR [29].
VDR expression was detected in villous trophoblast and decidua [31,32] and in smooth muscle
cells of the placental vessels (VSMC) [2]. Nuclei of stromal cells in fetal villi and in the nuclei
of fetal endothelial cells express also VDR [32]. VDR is known to regulate immune responses:
Calcitriol stimulates the synthesis of cathelicidin (CAMP), an antimicrobial peptide, in trophoblasts,
decidual cells and placental macrophages [30]. 1,25(OH)2D3 decreases synthesis of cytokines including
tumor necrosis factor, granulocyte-macrophage colony stimulating factor, and interleukin-6 in
decidua [33], these results indicate that the vitamin D system may play an important role in controlling
placental responses to infection. For example, placental synthesis of 1,25(OH)2D3 is induced by
lipopolysaccharides (LPS), a Toll-like receptor 4 ligand (TLR4) by upregulation of CYP27B1 in
mouse placenta [34].
Therefore, placental vitamin D system, including VDR, its ligands and the metabolizing enzymes
like CYP27B1 plays a key role, possibly in combination with other factors like cytokines to maintain
innate immunity and favours implantation [25,35].
3. VDR and Preeclampsia
Preeclampsia is defined by maternal hypertension, proteinuria and endothelial dysfunction,
this syndrome affects up to 8% of pregnancies. It causes significant maternal and perinatal morbidity
and mortality [36]. This accounts mostly for the severe, early onset form of preeclampsia, which has
important pathophysiological overlaps with fetal growth restriction, and usually comes along
with the latter. Placental insufficiency is a key characteristic of severe, early onset preeclampsia,
and in addition of pregnancies with fetal growth restriction (FGR). Decreased trophoblast invasion,
impaired placentation, disturbed remodeling of uterine arterioles [37], reduced cytotrophoblast
proliferation and increased apoptosis [38] are specific observations in placental insufficiency.
Vitamin D deficiency is connected to placental insufficiencies like preeclampsia and fetal
growth restriction. Several observational studies found significant associations between Vitamin
D levels and an elevated risk of preeclampsia or gestational hypertension diseases [39–42], but overall
results are conflicting: Three cohort studies and three case–control studies weren’t able to identify
a link between plasma 25(OH)D concentration and preeclampsia. Observations linked maternal
Vitamin D and early onset and severe preeclampsia, but there was no association between maternal
Vitamin D and late onset preeclampsia or overall preeclampsia risk [42,43]. However, the results
are difficult to compare because of heterogeneity of populations, geographic location and lack of
technical standardization in measurements. Other confounding factors, which influence vitamin
D levels, are ethnicity, dietary habits, lifestyle and gestational age at sampling.
3.1. VDR Expression Changes in Preeclampsia
As to the specific placental metabolism, preeclampsia has recently been associated with
decreased activation, increased catabolism, and impaired placental uptake of 25(OH)D3 [44].
In preeclampsia, which has significant pathophysiological overlaps with FGR, VDR expression is
decreased [45–47]. Furthermore, placentas of preeclamptic women have reduced CYP27B1 enzyme
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activity in comparison to regular pregnancies [13]. One hypothesis connecting low vitamin D to
the pathophysiology of preeclampsia is that vitamin D deficiency causes imbalances between Th1 to
Th2 cytokines, while higher Th1 cytokine impairs embryo implantation [48]. Disturbed extravillous
trophoblast (EVT) invasion of decidua and maternal spiral arteries is a key feature of preeclampsia
and gestational hypertension. Recent data showed that calcitriol and calcidiol significantly increased
EVT invasion in vitro [49]. Furthermore, in vitamin D deficiency is endothelial function of placental
vessels disturbed and VDR expression on placental endothelium disturbed [23,50]. As genetic and
epigenetic factors regulate protein expression, previous studies have reported that the placental
Vitamin D concentration is influenced by epigenetic DNA methylation especially CYP24AI [51,52].
Therefore, hypermethylation of VDR gene may cause the downregulation of placental VDR in
FGR-or preeclampsia.
3.2. Role of VDR Polymorphisms in Preeclampsia
There is a strong association between common VDR polymorphisms, as e.g., BsmI and FokI, and
hypertension risk outside pregnancy [53–55]. In cell cultures, VDR-dependent signaling directly
suppressed renin gene transcription [56]. FokI polymorphism of VDR influences plasma renin
activity [57] and seems to be associated with a decreased risk of hypertension. Although there
is also some evidence for a genetic contribution to hypertensive disorders of pregnancy [58–60],
a recent case-control study found the three common VDR SNPs (FokI, ApaI and BsmI) equally
distributed in gestation hypertension groups compared with healthy pregnancy cohort. In this study,
neither these VDR genetic polymorphisms nor VDR haplotypes predisposed to preeclampsia or
gestational hypertension [59].The authors concluded that other VDR polymorphisms might affect the
risk of getting preeclampsia or gestational hypertension, as the VDR gene is very large (over 100,000
base pairs) [56,61].
4. VDR and Fetal Growth Restriction
Fetal growth restriction (FGR) is a major health concern as it applies up to 5% of all pregnancies
worldwide and is an important cause of perinatal mortality and morbidity [62]. Defining criteria
include birth weight of less than the 10th centile for gestation and other signs of danger for the fetus,
as e.g., low amniotic fluid s or asymmetric fetal growth [63]. A growth retarded fetus misses its
genetically predetermined size for gestational age [64], this is the important difference too small for
gestational age infants (SGA). FGR causes perinatal complications, for example an increased rate of
stillbirth or prematurity. These children are at higher risk for several diseases, including cardiovascular
disease and diabetes [65,66], asthma [67], or neurological sequelae as intellectual developmental
delay [68], schizophrenia [69], depression [70].
FGR has multiple underlying reasons, as e.g., fetal chromosomal abnormalities, maternal nicotine
abuse and malnutrition. However ~70% of the cases are called idiopathic FGR as there is no
evident reason to identify [71]. Characteristic signs of idiopathic FGR include is impaired function
of uteroplacental vessels, including disturbed placental development and reduced flow from uterine
vessels to the placenta [72]. The molecular pathophysiology is still not completely understood.
The possible mechanisms, which link vitamin D to fetal growth, are calcium metabolism,
bone growth or altered placental function [73]. Vitamin D regulates via the VDR pathway human
chorionic gonadotropin expression and secretion in human synctiotrophoblasts [2] and increases
placental sex steroid production [24]. As it is explained in detail later in the manuscript, Vitamin D is also
important in glucose/insulin homeostasis and for transplacental transport and fetal usage of glucose [74].
A systematic review linked maternal 25(OH)D and fetal growth by ultrasound [75] and several
observational studies found associations between vitamin d levels and fetal growth [76–78]. Nevertheless,
the results of the observational studies are conflicting: A multiethnic cohort study of pregnant women
with vitamin D deficiency couldn’t identify a link between maternal vitamin D levels and any of the
neonatal anthropometric measures [79].
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FGR placentae show significant different placental morphology such as reduced villous tree
elaboration and diminished surface area [38]. In addition, trophoblast invasion and cytotrophoblast
proliferation [38] is reduced, cytotrophoblast apoptosis [80] is increased. Additionally, the fusion of
the villous trophoblast forming the multi-nucleated syncytiotrophoblast is impaired in placenta of
FGR [37,81].
4.1. VDR Expression and Signaling in Fetal Growth Restriction
VDR regulates cell proliferation and differentiation [82]. As mentioned above, VDR varies
during pregnancy [31]. Placental VDR expression is decreased in human FGR and causes trophoblast
dysfunction [83]. Therefore, decreased VDR expression may impair the actions and limits the beneficial
effects of vitamin D in the regulation of feto-placental growth.
In in vitro studies, VDR plays critical roles in the maintenance of proliferation, migration,
differentiation and apoptosis of the trophoblasts. This may be a link between the pathology of idiopathic
FGR-affected pregnancies and the reduced VDR expression in such cases [23]. Placentae of FGR
patients show impaired villous trophoblast fusion forming the syncytiotrophoblast [37,81,84]. VDR is
a critical regulator of placental hormone secretion e.g., placental lactogen and β-hCG in BeWo cells.
BeWo cells work well as in vitro model for the syncytiotrophoblasts [27,85,86]. VDR regulates BeWo
cell differentiation via the influence on β-hCG expression. Furthermore, VDR inactivation affects
syncytium formation in vitro and VDR inactivation promotes apoptosis, using TP53 mRNA as a
marker of apoptosis [83]. Trophoblast syncytialisation is connected to decreased CYP27B1 in vitro [87].
VDR plays a role in protection against extrinsic apoptosis in placental insufficiency and maintains
proper trophoblast function under adverse conditions like FGR [23]. As mentioned above, genetic and
epigenetic regulations influence vitamin D effects on feto-placental development [88] and methylation
changes in the VDR gene may reduce VDR expression in FGR [51,52].
4.2. VDR Polymorphisms in Fetal Growth Restriction
In addition, decreased expression of VDR in FGR may be due to SNPs of VDR, as polymorphisms
influence expression and function of VDR [22,89]. VDR polymorphisms have been shown to modify
offspring size; this was shown for the FokI genotype, but not for ApaI, BsmI, TaqI genotype. The latter
have a high linkage disequilibrium in Caucasian population [90]. The ApaI polymorphism (rs7975232)
is a non coding polymorphism of the VDR gene. Along with TaqI polymorphism (rs731236) this
SNPs are associated with variation in mRNA stability [18]. As this influences the amount of protein,
they might be able to change vitamin D levels and calcium homeostasis. However, the effect of a distinct
maternal polymorphism on birthweight seems to differ across racial groups. In a prospective cohort
study in North Carolina, a strong correlation between ApaI (rs7975232) and birthweight was identified
in black mothers, but there was no association between any VDR SNP and birthweight for white
mothers [91]. Common polymorphisms of VDR, which are associated with pregnancy complications,
are listed in Table 1.
Table 1. Vitamin D Receptor (VDR) polymorphisms in pregnancy complications.
Polymorphism Pregnancy Complication
FokI
Preterm birth
Gestational diabetes
Influence on offspring size
ApaI
Preterm birth
Gestational diabetes
Influence on Birth weight
TaqI Gestational diabetes
Table 1 shows the most common polymorphisms, which are associated with pregnancy complications in
certain populations.
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5. VDR and Diabetes in Pregnancy
Gestational diabetes mellitus is a state of pronounced peripheral insulin resistance, which
results in glucose intolerance in the second half of pregnancy. This concerns 3% to 8% of all
pregnancies depending on geographical location [92–94]. On one hand, GDM increases the risk
of adverse pregnancy outcomes, as e.g., intrauterine fetal demise, fetal macrosomia, birth trauma
and preeclampsia [95]. On the other hand, GDM influences health issues in later life of both mothers
and their offspring, as overweight, type 2 diabetes mellitus (T2DM) and metabolic syndrome [96,97].
Vitamin D deficiency has been linked with insulin resistance in pregnancy [98] and with an increased
risk of GDM [8]. Several studies have reported lower Vitamin D levels in women with GDM [8,99,100]
or in the first half of pregnancy among women who later developed GDM. However, these results
are controversial [101,102], other studies didn’t see an association between Vitamin D levels and
GDM [102,103]. The influence of individual, lifestyle and geographical factors on Vitamin D status
is complex. Skin pigmentation, sun exposure, adiposity and diet are known to influence vitamin D.
In addition, physical activity increases sun exposure and decreases body weight, as well as potentially
the risk of GDM. In a large birth cohort study women with vitamin D deficiency had higher odds
of GDM [104], but that this association diminished after adjustment for different confounders.
Overall, systematic reviews and meta-analyses found a modest raise for the risk of GDM [73,105].
The outcome of these analyses are restricted by cohorts from different regions, the varying laboratory
standards and timing of measurement of serum 25(OH)D level. The quantity of the effect of some
influencing factors like ethnicity and adiposity are still unclear [106]. Until now, the exact mechanisms
underlying the association of vitamin D and insulin resistance are not fully understood: In general,
Vitamin D regulates about 3% of the human genome, especially genes that influence glucose and
lipid metabolism [107,108]. The following models link the pathogenesis of GDM with low levels
of vitamin D [109–112]: Several studies demonstrated specific receptors for vitamin D in pancreatic
β cells [113] and a role for vitamin D in the secretion of insulin [114,115]. It also has been reported that
vitamin D deficiency is associated with insulin resistance and T2DM [116,117].
Vitamin D regulates the balance between extra- and intracellular calcium. Calcium is an essential
co-factor for insulin-mediated intracellular functions in insulin-depending tissues such as skeletal
muscle and adipose tissue [118–120]. It is responsible for adequate insulin-mediated functions [121].
Changes in intracellular calcium contribute to peripheral insulin resistance as Calcium has to be in
a very distinct range [121]. Insulin receptor phosphorylation is a calcium depending function as
well [122]. Changes in Calcium concentration influences insulin signal transduction [120,123] and
leads to decreased glucose transporter GLUT-4 activity [123,124].The promoter region of the human
insulin gene contains Vitamin D response element (VDRE) [123,125] and so transcription of the human
insulin gene is upregulated by 1,25(OH)D2 [126].
VDR influences glucose homeostasis via the insulin-like growth factor system. Vitamin D
has an impact on the immune system [127] as VDRE is part of the promoter region of certain
cytokines and has impact on cytokine generation and action [128–130] as for example NF-kB [130,131].
This is an important regulator of genes encoding pro-inflammatory cytokines implicated in insulin
resistance [132] or calbindin [133,134], a cytosolic calcium-binding protein found in many tissues
including pancreatic beta cells [134]. GDM is a proinflammatory state like preexisting diabetes [135].
Deficiency in immune modulations e.g., via itamin D deficiency causes an severe inflammatory
response, which is an essential part of insulin resistance [136].
5.1. VDR Expression in Gestational Diabetes Mellitus
As to placental VDR expression changes in GDM, our recent work showed increased levels of
VDR in extravillous trophoblasts and fetoplacental endothelium associated with maternal GDM [93].
Vitamin D protects endothelial tissue against renovascular dysfunction [137]. As Vitamin D induces
NO production in endothelial cells, and endothelial dysfunction in GDM is accompanied by increased
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NO production, this link seems probable for GDM. Possibly, upregulation of VDR in the fetoplacental
endothelium is a result of low vitamin D levels even in the fetus [93].
EVT displayed the strongest VDR upregulation of all placental parts [93]. EVT, which forms
the fetomaternal interface, prevents allo-recognition and attacking of fetal cells by maternal natural
killer cells, cytotoxic T cells, and macrophages [138]. As shown above vitamin D supports the immune
system in both maternal and fetal compartments [33,34,139] and it is a key regulator of placental
inflammation [34]. GDM is an pro-infammatory state and VDR upregulation seems to compensate
Vitamin D deficiency. A different study from Cho and co-workers [140] found no differences in
VDR expression in GDM placenta, but they did not separate villous and extravillous trophoblasts.
They found increased expression and production of CYP24A1 from patients with GDM compared with
normal placental tissues and that serum vitamin D level was correlated negatively with the expression
of CYP24A1 in placenta. They concluded that increased placental expression and production of
CYP24A1 may be responsible for the low level of vitamin D that is observed in GDM [140].
5.2. VDR Polymorphisms and Gestational Diabetes Mellitus
Available data suggest that GDM has genetic endowments in combination with environmental
impacts [141]. Mothers with GDM often have a family history of diabetes and GDM recurs in
at least 30% of women with a history of GDM [142,143], even in different populations [144,145].
VDR polymorphisms have been linked to a higher risk for type 1 diabetes mellitus (T1DM) [146,147]
and type 2 diabetes mellitus (T2DM) [148]. As GDM and T2DM have a similar pathophysiology [149],
polymorphisms in genes predisposing for diabetes mellitus Type 2 are closely related to GDM
susceptibility [150]. Some VDR polymorphisms are strongly influencing the susceptibility to diabetes
in general [148,151]: BsmIBB, BsmIBb, and TaqItt polymorphisms are linked to susceptibility of
T1DM [152]. However, the connection between BsmI SNP and T2DM is weak. In a Chinese cohort,
FokI polymorphism was significantly linked to T2DM risk, but not in Caucasians [153].
For the effect of VDR polymorphisms in GDM, only a few studies are available. A link between
VDR ApaI, TaqI, and FokI SNPs and risk for GDM was suggested in Iranian, Chinese and Saudi
Arabian population [144,145]. But results with contrasting findings are available, as El-Beshbishy et al.
couldn’t link VDR BsmI and FokI polymorphism and GDM in a Saudi population [154]. In Chinese
female genetic variants of Vitamin D binding protein and the heterodimers RXRα and γ had been
identified as susceptibility markers for GDM [155]. See also Table 1 for common polymorphisms
of VDR, which are associated with pregnancy complications.
To conclude, further studies are warranted with sufficient statistical power and with different
ethnic background in order to confirm the potential of genetic biomarkers for prediction of GDM in
different populations.
6. VDR and Preterm Birth
Preterm birth (PTB) is one of the leading problems in modern obstetrics. Deaths among premature
infants account for 70% of all perinatal mortalities. The surviving ones are at risk for chronic lung
disease, hearing, visual and cognitive impairments [156]. Hence, the pathophysiology of preterm
birth is still unknown and heterogeneous, obviously intrauterine infection is a frequent and important
mechanism causing early delivery [157]. Pro-inflammatory cytokines and genes probably trigger
delivery at term [158]. Therefore, early excessive cytokine productions because of infection can lead to
preterm labor.
Even though Vitamin D modulates immune responses and plays an important role in defending
infections [127,159], findings from randomized [160] and epidemiologic studies of Vitamin D and
preterm birth are controversial [76,161–164]. However, a very recent meta-analysis of 18 studies of
either observational or interventional design, found sufficient evidence linking Vitamin D insufficiency
with PTB. Serum 25(OH)D levels <75 nmol/l was associated with 13% and 83% increased risk of PTB
measured at <35–37 weeks and <32–34 weeks, respectively [165]. An inverse dose-response relation
Int. J. Mol. Sci. 2017, 18, 2340 8 of 18
was noted for both PTB outcomes consistent with previous work linking maternal Vitamin D deficiency
to bacterial vaginosis [166].
6.1. VDR Signaling in Preterm Birth
Experimental studies found associations between maternal Vitamin D status and placental
antibacterial responses [30,33]. Toll-like receptors initiate the innate immune defense against
microbial pathogens. Vitamin D reduces bacterial infections by inducing cathelicidin in decidua
and cytotrophoblasts [139,167]. Low Vitamin D impairs toll-like receptor induction of the antimicrobial
peptide cathelicidin from systemic macrophages [139]. Furthermore, calcitriol decreases expression
of cytokines, such as granulocyte macrophage colony stimulating factor 2 (GMCSF-2), TNF-α, IL-6.
LPS increases inflammatory reactions in myometrial tissue [168] and myometrial smooth muscle
(UtSM) cells [169]. LPS and IL-1β trigger preterm delivery in rodent models [170,171]. Vitamin D
decreases both LPS- and IL-1β-induced proteins in UtSM cells [172]. Therefore, Vitamin D attenuates
the inflammation-induced expression of contractile-associated proteins in UtSM cells [34].
6.2. Role of VDR Polymorphisms in Preterm Birth
Information is sparse about association between preterm birth and VDR polymorphisms.
BsmI, TaqI, ApaI, FokI SNPs were investigated by comparing maternal and neonatal genotype
frequencies between the term and preterm cohorts.
In an Isreali population, the genotype frequencies of the VDR ApaI polymorphisms differed
between term and preterm cohorts. Women carrying the VDR ApaI homozygote genotype had a higher
risk for preterm births compared to the heterozygote group. This remained significant after adjustment
for confounders. They couldn’t find a link between VDR BsmI, TaqI or FokI variation frequencies
between preterm and term births [173].
Manzon et al. investigated FokI, ApaI, TaqI and BsmI SNPs concerning the risk of spontaneous
preterm birth in an Israeli population. In this population, maternal FokI and TaqI VDR allele frequencies
were significantly different in the preterm birth group. However, only maternal FokI variant could be
linked to an increased risk of preterm birth (odds ratio OR = 3.317). The ORs for the other variants
such as TaqI, BsmI or ApaI were insignificant [19]. In addition, work from a polish group indicates that
individual maternal SNPs of the VDR gene, namely the TaqI, BsmI and ApaI polymorphisms, had no
effect on preterm birth. But they investigated some genotype combinations and e.g., some combinations
reduced the risk for preterm birth significantly [174]. Polymorphisms of VDR, which are associated
with pregnancy complications, are listed in Table 1.
7. Existing Knowledge from VDR Knock-Out Models
As elucidated above, common pregnancy complications are associated with impaired trophoblast
function and impaired immune regulation on the feto-maternal interface. Even if we have multiple
experimental and observational studies, a clear mechanistic link between VDR expression and placental
function and therefore fetal outcome is still missing. Proper designed investigations with VDR
knockout dams may add important knowledge in this area:
VDR knockout (Vdr−/−) mice had lower fetal weights in comparison to heterozygous (Vdr+/−)
animals [175]. As mentioned above, investigations in knockout VDR and Cyp27b1 knockout mice
showed that Vitamin D controls placental inflammation [34]. Wilson et al. found no differences in
morphology of Vdr−/− fetus or placenta, when the Vdr+/− mother was fed with sufficient vitamin D
and calcium [176]. Dams with a vitamin D deficient diet had reduced placental size [177]. The authors
concluded that it might be the decidua, which mediates the impact of low maternal vitamin D on
the placenta, rather than direct VDR signaling in the placenta [176]. Interestingly, the authors detected
that especially some genes which are involved in oxidative stress and fetal growth are different between
Vdr−/− and Vdr+/+ placentae [176]. This might be a link to development of pregnancy complications
like preeclampsia [178].
Int. J. Mol. Sci. 2017, 18, 2340 9 of 18
8. Conclusions
To conclude, the evidence out of experimental studies is convincing, Vitamin D together with the
placental nuclear receptor VDR has important impact on the fetomaternal unit in multiple pathways.
VDR influences trophoblast differentiation and function, regulates immune reactions and inflammation.
However, existing clinical studies give conflicting results about the impact of vitamin D in
pregnancy disorders. Vitamin D status is influenced by dietary habits, skin pigmentation, sun exposure,
adiposity and missing standardization of measurements. These factors hinder proper design and
reproducibility of clinical studies. Furthermore, the relationship between a polymorphism and
phenotype cannot be clarified upon in studies where individual SNPs are analyzed in isolation
and interpretation of association studies involving the VDR gene are difficult because most of the SNPs
are non-coding. The aim of further designed studies should be to investigate the functional haplotype
structure of VDR polymorphisms in different populations.
Taken together the knowledge about vitamin D and placental VDR, we assume that disturbances
in VDR expression and function, which result in pregnancy complications, may refer mainly to the
maternal part of the placenta. Information about the consequences of defective VDR signaling in the
fetus or the fetal part of the placenta are still missing, especially regarding the long time outcome of
the offspring. Further investigations, which distinguish properly between fetal and maternal parts of
the placenta and provide data about fetal programming, are warranted for the prevention of vitamin
D related diseases in the offspring.
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